Christine A Iacobuzio-Donahue

List of Publications by Year
in descending order

319 papers	60,309 citations	1614 105 h-index	1009 236 g-index
338 all docs	338 docs citations	338 times ranked	59323 citing authors

#	Article	IF	Citations
1	MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma. Cancer Discovery, 2022, 12, 542-561.	9.4	35
2	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	28.9	223
3	MITI minimum information guidelines for highly multiplexed tissue images. Nature Methods, 2022, 19, 262-267.	19.0	37
4	Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts. Nature Communications, 2022, 13, 2144.	12.8	18
5	Evidence for reduced BRCA2 functional activity in Homo sapiens after divergence from the chimpanzee-human last common ancestor. Cell Reports, 2022, 39, 110771.	6.4	5
6	Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature, 2022, 606, 389-395.	27.8	80
7	Concurrent Germline BRCA1/2 and Mismatch Repair Mutations in Young-Onset Pancreatic and Colorectal Cancer: The Importance of Comprehensive Germline and Somatic Characterization to Inform Therapeutic Options. JCO Precision Oncology, 2022, , .	3.0	2
8	Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Gastroenterology, 2021, 160, 362-377.e13.	1.3	90
9	Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients. Cancer Cell, 2021, 39, 276-283.e3.	16.8	54
10	Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001. Clinical Cancer Research, 2021, 27, 2111-2118.	7.0	5
11	Artificial Intelligence and Early Detection of Pancreatic Cancer. Pancreas, 2021, 50, 251-279.	1.1	71
12	Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes. Journal of the National Cancer Institute, 2021, 113, 1194-1202.	6.3	35
13	Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma. BMC Cancer, 2021, 21, 385.	2.6	24
14	Pancreatic cancer prognosis is predicted by an ATAC-array technology for assessing chromatin accessibility. Nature Communications, 2021, 12, 3044.	12.8	19
15	Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation. Cancer Discovery, 2021, 11, 3028-3047.	9.4	66
16	The pancreatic cancer genome revisited. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 469-481.	17.8	100
17	Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes. Cancer, 2021, 127, 4393-4402.	4.1	24
18	The mutational landscape of human somatic and germline cells. Nature, 2021, 597, 381-386.	27.8	180

#	Article	IF	Citations
19	The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas. Clinical Cancer Research, 2021, 27, 1516-1525.	7.0	6
20	Methylation-based Cell-free DNA Signature for Early Detection of Pancreatic Cancer. Pancreas, 2021, 50, 1267-1273.	1.1	18
21	ID1 Mediates Escape from TGFÎ² Tumor Suppression in Pancreatic Cancer. Cancer Discovery, 2020, 10, 142-157.	9.4	59
22	Fumarate hydrataseFHc.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma. Human Mutation, 2020, 41, 103-109.	2.5	25
23	Intratumor heterogeneity reflects clinical disease course. Nature Cancer, 2020, 1, 3-6.	13.2	44
24	A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma. Nature Cancer, 2020, 1, 59-74.	13.2	124
25	Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis. Science, 2020, 369, 276-282.	12.6	146
26	Accelerated single cell seeding in relapsed multiple myeloma. Nature Communications, 2020, 11, 3617.	12.8	41
27	Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 30670-30678.	7.1	11
28	Pancreatic cancers suppress negative feedback of glucose transport to reprogram chromatin for metastasis. Nature Communications, 2020, 11, 4055.	12.8	19
29	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Cell Reports, 2020, 31, 107625.	6.4	78
30	Simple mucinous cysts of the pancreas have heterogeneous somatic mutations. Human Pathology, 2020, 101, 1-9.	2.0	14
31	Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells. Cell, 2020, 181, 1643-1660.e17.	28.9	554
32	Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Cancer, 2020, 126, 3939-3949.	4.1	44
33	The Evolutionary Origins of Recurrent Pancreatic Cancer. Cancer Discovery, 2020, 10, 792-805.	9.4	71
34	Genetic and clinical correlates of entosis in pancreatic ductal adenocarcinoma. Modern Pathology, 2020, 33, 1822-1831.	5.5	40
35	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell, 2020, 181, 236-249.	28.9	334
36	The mutational landscape of normal human endometrial epithelium. Nature, 2020, 580, 640-646.	27.8	338

#	Article	IF	Citations
37	iNOS Regulates the Therapeutic Response of Pancreatic Cancer Cells to Radiotherapy. Cancer Research, 2020, 80, 1681-1692.	0.9	31
38	Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. Clinical Cancer Research, 2020, 26, 3239-3247.	7.0	135
39	Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. Journal of Clinical Investigation, 2020, 130, 6668-6676.	8.2	28
40	Young-onset pancreas cancer (PC) in patients less than or equal to 50 years old at Memorial Sloan Kettering (MSK): Descriptors, genomics, and outcomes.. Journal of Clinical Oncology, 2020, 38, 774-774.	1.6	5
41	Initial Whole Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001. Blood, 2020, 136, 50-51.	1.4	0
42	TCR Repertoires in Graft-Versus-Host-Disease (GVHD)-Target Tissues Reveals Tissue Specificity of the Alloimmune Response. Blood, 2020, 136, 21-23.	1.4	1
43	Stakeholders' Perceptions and Information Needs Regarding Research Medical Donation. Journal of Pain and Symptom Management, 2019, 58, 792-804.e6.	1.2	2
44	CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma. Abdominal Radiology, 2019, 44, 3148-3157.	2.1	37
45	An analysis of genetic heterogeneity in untreated cancers. Nature Reviews Cancer, 2019, 19, 639-650.	28.4	139
46	Cancer biology as revealed by the research autopsy. Nature Reviews Cancer, 2019, 19, 686-697.	28.4	54
47	Cell division rates decrease with age, providing a potential explanation for the age-dependent deceleration in cancer incidence. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20482-20488.	7.1	63
48	Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. Clinical Epigenetics, 2019, 11, 59.	4.1	106
49	Characterization of genetic subclonal evolution in pancreatic cancer mouse models. Nature Communications, 2019, 10, 5435.	12.8	14
50	Longitudinal follow-up of a prospective phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma reveals distinct patterns of survivorship. Hpb, 2019, 21, S58-S59.	0.3	0
51	EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. Cancer Discovery, 2019, 9, 199-209.	9.4	115
52	Genomic Landscape of Pancreatic Adenocarcinoma in Younger versus Older Patients: Does Age Matter?. Clinical Cancer Research, 2019, 25, 2185-2193.	7.0	41
53	Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes. Cancer, 2019, 125, 1441-1448.	4.1	28
54	Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1692-1697.	7.1	237

#	Article	IF	Citations
55	Homologous recombination deficiency (HRD): A biomarker for first-line (1L) platinum in advanced pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2019, 37, 4132-4132.	1.6	10
56	Pilot study of plasma KRAS as a prognostic biomarker in localized pancreas ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2019, 37, 294-294.	1.6	0
57	Association of pancreatic cancer stem cells with tumor stroma type.. Journal of Clinical Oncology, 2019, 37, e15771-e15771.	1.6	0
58	Abstract 970: The mutational landscape of normal human endometrial epithelium. Cancer Research, 2019, 79, 970-970.	0.9	4
59	Abstract 3083: A novel hedgehog signaling inhibitor for targeting pancreatic ductal adenocarcinoma. , 2019, , .		1
60	Abstract I07: Multimodal evolutionary dynamics of pancreatic cancer. , 2019, , .		0
61	Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. Journal of the National Cancer Institute, 2018, 110, 1067-1074.	6.3	170
62	Unifying cancer and normal RNA sequencing data from different sources. Scientific Data, 2018, 5, 180061.	5.3	152
63	Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas, 2018, 47, 208-212.	1.1	28
64	Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Clinical Cancer Research, 2018, 24, 1326-1336.	7.0	281
65	Minimal functional driver gene heterogeneity among untreated metastases. Science, 2018, 361, 1033-1037.	12.6	223
66	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell, 2018, 34, 427-438.e6.	16.8	633
67	Precancerous neoplastic cells can move through the pancreatic ductal system. Nature, 2018, 561, 201-205.	27.8	96
68	Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science, 2018, 360, .	12.6	177
69	Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discovery, 2018, 8, 1112-1129.	9.4	676
70	Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis. Gastroenterology, 2018, 155, 668-673.	1.3	87
71	Plasma KRAS as a biomarker for pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2018, 36, 316-316.	1.6	2
72	Prospective analysis of somatic and germline genetic alterations in patients with ampullary carcinomas.. Journal of Clinical Oncology, 2018, 36, 308-308.	1.6	0

#	Article	IF	Citations
73	Whole Genome Sequencing of Extramedullary Myeloma Autopsy Tumors Reveals a Genomic Portrait at Culmination of Clonal Convergence. Blood, 2018, 132, 3169-3169.	1.4	1
74	Mytype: A Capture Based Sequencing Approach to Detect Somatic Mutations, Copy Number Changes and IGH Translocations in Multiple Myeloma. Blood, 2018, 132, 5588-5588.	1.4	0
75	Stakeholders' perceptions and information needs regarding research medical donation (RMD).. Journal of Clinical Oncology, 2018, 36, 27-27.	1.6	5
76	Reconstructing metastatic seeding patterns of human cancers. Nature Communications, 2017, 8, 14114.	12.8	118
77	Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis. Nature Genetics, 2017, 49, 367-376.	21.4	365
78	Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nature Genetics, 2017, 49, 358-366.	21.4	316
79	Molecular pathology of pancreatic cancer and premalignant tumors. , 2017, , 139-149.e3.		0
80	Transcriptional Mechanisms of Resistance to Antiâ€“PD-1 Therapy. Clinical Cancer Research, 2017, 23, 3168-3180.	7.0	67
81	Alterations of type II classical cadherin, cadherinâ€10 (CDH10), is associated with pancreatic ductal adenocarcinomas. Genes Chromosomes and Cancer, 2017, 56, 427-435.	2.8	8
82	Personalized Management of Pancreatic Ductal Adenocarcinoma Patients through Computational Modeling. Cancer Research, 2017, 77, 3325-3335.	0.9	11
83	Pancreatic carcinogenesis â€" several small steps or one giant leap?. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 7-8.	17.8	24
84	Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Clinical Cancer Research, 2017, 23, 6094-6100.	7.0	161
85	Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 2017, 551, 512-516.	27.8	854
86	An unusual genomic variant of pancreatic ductal adenocarcinoma with an indolent clinical course. Journal of Physical Education and Sports Management, 2017, 3, a001701.	1.2	6
87	Hypermutation In Pancreatic Cancer. Gastroenterology, 2017, 152, 68-74.e2.	1.3	174
88	Mutant p53 Together with TGFÎ² Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer. Clinical Cancer Research, 2017, 23, 1607-1620.	7.0	37
89	Prospective assessment for pathogenic germline alterations (PGA) in pancreas cancer (PAC).. Journal of Clinical Oncology, 2017, 35, 4102-4102.	1.6	4
90	Local recurrences at the anastomotic area are clonally related to the primary tumor in sporadic colorectal carcinoma. Oncotarget, 2017, 8, 42487-42494.	1.8	10

#	Article	IF	Citations
91	Tumor diversity and evolution revealed through RADseq. Oncotarget, 2017, 8, 41792-41805.	1.8	9
92	Do pancreas cancer stem cells play crucial role in survival outcome?. Journal of Clinical Oncology, 2017, 35, e15721-e15721.	1.6	0
93	Abstract 2829: Identification of transcriptomic signatures of organotropism in pancreatic cancer metastasis. , 2017, , .		0
94	Abstract 504: Quantification of nucleic acid quality in postmortem tissues from a cancer research autopsy program. , 2017, , .		0
95	Abstract 2910: Inter metastatic genetic heterogeneity is a characteristic feature of recurrent pancreatic cancer. , 2017, , .		0
96	Recurrent, truncating SOX9 mutations are associated with SOX9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma. Oncotarget, 2016, 7, 50875-50882.	1.8	26
97	Reliable Detection of Somatic Mutations in Fine Needle Aspirates of Pancreatic Cancer With Next-generation Sequencing. Annals of Surgery, 2016, 263, 153-161.	4.2	45
98	ETS-Transcription Factor ETV1 Regulates Stromal Expansion andÂMetastasis in Pancreatic Cancer. Gastroenterology, 2016, 151, 540-553.e14.	1.3	44
99	Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Annals of Surgery, 2016, 264, 1073-1081.	4.2	131
100	p120 Catenin Suppresses Basal Epithelial Cell Extrusion in Invasive Pancreatic Neoplasia. Cancer Research, 2016, 76, 3351-3363.	0.9	29
101	TGF-Î² Tumor Suppression through a Lethal EMT. Cell, 2016, 164, 1015-1030.	28.9	488
102	Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nature Medicine, 2016, 22, 497-505.	30.7	456
103	Cyst Fluid Analysis in Pancreatic Intraductal Papillary Mucinous Neoplasms. Clinical Cancer Research, 2016, 22, 4966-4967.	7.0	5
104	Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 523-532.	2.8	65
105	Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer. Practical Radiation Oncology, 2016, 6, 417-424.	2.1	19
106	Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies. Cell Reports, 2016, 17, 2445-2459.	6.4	450
107	Pancreatic cancer biology and genetics from an evolutionary perspective. Nature Reviews Cancer, 2016, 16, 553-565.	28.4	316
108	Metastatic progression is associated with dynamic changes in the local microenvironment. Nature Communications, 2016, 7, 12819.	12.8	99

#	Article	IF	Citations
109	IGFBP-3 Gene Methylation in Primary Tumor Predicts Recurrence of Stage II Colorectal Cancers. Annals of Surgery, 2016, 263, 337-344.	4.2	21
110	The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes. Modern Pathology, 2016, 29, 1058-1069.	5.5	82
111	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Cancer Discovery, 2016, 6, 166-175.	9.4	282
112	Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1-13.	3.0	39
113	Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 2016, 531, 47-52.	27.8	2,700
114	p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells. Oncogene, 2016, 35, 4282-4288.	5.9	108
115	Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. Expert Opinion on Therapeutic Targets, 2016, 20, 341-359.	3.4	34
116	Quantification of nucleic acid quality in postmortem tissues from a cancer research autopsy program. Oncotarget, 2016, 7, 66906-66921.	1.8	17
117	Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients. Oncotarget, 2016, 7, 86480-86489.	1.8	15
118	Genomic landscape of pancreatic adenocarcinoma: Does age matter?. Journal of Clinical Oncology, 2016, 34, 250-250.	1.6	0
119	Do pancreatic cancer (PDA) stem cell markers predict biologic behavior?. Journal of Clinical Oncology, 2016, 34, 4112-4112.	1.6	0
120	Abstract 2374: Reconstructing the evolutionary history of metastatic cancers. , 2016, , .		0
121	Abstract 2419: Anastomotic recurrences are clonally related to primary tumors in sporadic colorectal carcinoma. , 2016, , .		0
122	Abstract PR03: Mutant p53 promotes adenocarcinoma in pancreatic ductal cells. , 2016, , .		0
123	Whole Exome Sequencing from Nine Independent Sites of Extraosseous Disease in a Single Patient with Relapsed Multiple Myeloma Show That Extramedullary Disease Arise through a Combination of Branched and Parallel Evolution. Blood, 2016, 128, 2090-2090.	1.4	0
124	Transflip mutations produce deletions in pancreatic cancer. Genes Chromosomes and Cancer, 2015, 54, 472-481.	2.8	9
125	The Hidden Beauty in Biomedical Imaging. Journal of Visual Communication in Medicine, 2015, 38, 220-227.	0.6	1
126	Organoid Models of Human and Mouse Ductal Pancreatic Cancer. Cell, 2015, 160, 324-338.	28.9	1,584

#	Article	IF	Citations
127	CNS Involvement in Pancreatic Adenocarcinoma: a Report of Eight Cases from the Johns Hopkins Hospital and Review of Literature. Journal of Gastrointestinal Cancer, 2015, 46, 5-8.	1.3	20
128	Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 2015, 518, 495-501.	27.8	2,132
129	Are We Systematically Under-Dosing Patients With Fluorouracil?. Journal of Clinical Oncology, 2015, 33, e36-e37.	1.6	8
130	Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer. Science Signaling, 2015, 8, ra77.	3.6	89
131	Phase 2 multiâ€institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer, 2015, 121, 1128-1137.	4.1	447
132	Retrotransposon insertions in the clonal evolution of pancreatic ductal adenocarcinoma. Nature Medicine, 2015, 21, 1060-1064.	30.7	127
133	Widespread somatic L1 retrotransposition occurs early during gastrointestinal cancer evolution. Genome Research, 2015, 25, 1536-1545.	5.5	121
134	A Quantitative System for Studying Metastasis Using Transparent Zebrafish. Cancer Research, 2015, 75, 4272-4282.	0.9	113
135	Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nature Genetics, 2015, 47, 1168-1178.	21.4	1,491
136	MUC1 Promoterâ€“Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer. Molecular Cancer Research, 2015, 13, 439-448.	3.4	18
137	Abstract 4137: Clonal evolution defines the natural history of metastatic pancreatic cancer. , 2015, , .		3
138	Abstract A68: Hypoxia-induced CHK1 repression may enhance the mutator phenotype of pancreatic cancer cells. , 2015, , .		0
139	Abstract 4186: p120 catenin: A novel regulator of epithelial cell delamination in early Kras-driven pancreatic cancer. , 2015, , .		0
140	Processed pseudogenes acquired somatically during cancer development. Nature Communications, 2014, 5, 3644.	12.8	86
141	CpG island methylator phenotype and its association with malignancy in sporadic duodenal adenomas. Epigenetics, 2014, 9, 738-746.	2.7	7
142	The Tumor Suppressor rpl36 Restrains KRAS^{G12V}-Induced Pancreatic Cancer. Zebrafish, 2014, 11, 551-559.	1.1	24
143	dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer. Cancer Biology and Therapy, 2014, 15, 688-698.	3.4	39
144	Functional p38 MAPK Identified by Biomarker Profiling of Pancreatic Cancer Restrains Growth through JNK Inhibition and Correlates with Improved Survival. Clinical Cancer Research, 2014, 20, 6200-6211.	7.0	38

#	Article	IF	Citations
145	Autophagy, p53, and Pancreatic Cancer. New England Journal of Medicine, 2014, 370, 1352-1353.	27.0	35
146	The association between circulating high-sensitivity C-reactive protein concentration and pathologic measures of colonic inflammation. Cancer Causes and Control, 2014, 25, 409-418.	1.8	10
147	Long Interspersed Element-1 Protein Expression Is a Hallmark of Many Human Cancers. American Journal of Pathology, 2014, 184, 1280-1286.	3.8	250
148	A draft map of the human proteome. Nature, 2014, 509, 575-581.	27.8	1,948
149	Heterogeneity of Pancreatic Cancer Metastases in a Single Patient Revealed by Quantitative Proteomics. Molecular and Cellular Proteomics, 2014, 13, 2803-2811.	3.8	52
150	Hypersensitivities for Acetaldehyde and Other Agents among Cancer Cells Null for Clinically Relevant Fanconi Anemia Genes. American Journal of Pathology, 2014, 184, 260-270.	3.8	11
151	Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma. Cancer Cell, 2014, 25, 735-747.	16.8	1,616
152	Association of ALDH-expressing cancer stem cells with survival in patients with resected pancreatic adenocarcinoma treated with adjuvant chemoradiation.. Journal of Clinical Oncology, 2014, 32, 262-262.	1.6	0
153	Detection of somatic mutations in fine needle aspirates of pancreatic cancer with next-generation sequencing.. Journal of Clinical Oncology, 2014, 32, e15225-e15225.	1.6	0
154	Abstract 66: p120 catenin: A novel regulator of PanIN epithelial cell delamination in preinvasive pancreatic cancer. , 2014, , .		0
155	Molecular pathways in pancreatic carcinogenesis. Journal of Surgical Oncology, 2013, 107, 8-14.	1.7	70
156	Novel Methylation Biomarker Panel for the Early Detection of Pancreatic Cancer. Clinical Cancer Research, 2013, 19, 6544-6555.	7.0	129
157	Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumorâ€“vessel relationships. Journal of Radiation Oncology, 2013, 2, 413-425.	0.7	74
158	Pancreatic cancer genomics: insights and opportunities for clinical translation. Genome Medicine, 2013, 5, 26.	8.2	18
159	KRAS G>A mutation favors poor tumor differentiation but may not be associated with prognosis in patients with curatively resected duodenal adenocarcinoma. International Journal of Cancer, 2013, 132, 2502-2509.	5.1	13
160	FAM190A Deficiency Creates a Cell Division Defect. American Journal of Pathology, 2013, 183, 296-303.	3.8	25
161	Correlation of Smad4 Status With Outcomes in Patients Receiving Erlotinib Combined With Adjuvant Chemoradiation and Chemotherapy After Resection for Pancreatic Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2013, 87, 458-459.	0.8	21
162	Young Patients Undergoing Resection of Pancreatic Cancer Fare Better than their Older Counterparts. Journal of Gastrointestinal Surgery, 2013, 17, 339-344.	1.7	53

#	Article	IF	Citations
163	Evolution and dynamics of pancreatic cancer progression. Oncogene, 2013, 32, 5253-5260.	5.9	167
164	Considerations for Sequencing Analyses of Pancreatic Cancer Progression and Metastasis. Methods in Molecular Biology, 2013, 980, 121-129.	0.9	0
165	A Broad Survey of Cathepsin K Immunoreactivity in Human Neoplasms. American Journal of Clinical Pathology, 2013, 139, 151-159.	0.7	44
166	RhoC Interacts with Integrin Î±5Î²1 and Enhances Its Trafficking in Migrating Pancreatic Carcinoma Cells. PLoS ONE, 2013, 8, e81575.	2.5	20
167	The Genetics of Pancreatic Cancer Progression. , 2013, , 171-184.		0
168	Abstract IA5: Genetics of clonal progression in pancreatic cancer. , 2013, , .		0
169	Blood-based screening for methylation changes in colorectal cancer patients using novel nanotechnologies.. Journal of Clinical Oncology, 2013, 31, 384-384.	1.6	1
170	Abstract 3580: Acetaldehyde and drug hypersensitivities of Fanconi anemia defects: Implications for cancer initiation, prevention, and therapy.. , 2013, , .		0
171	Abstract 4006: Smad6 upregulation provides an alternative mechanism for BMP inactivation in SMAD4 wild type pancreatic cancers.. , 2013, , .		1
172	Is successful resection following neoadjuvant radiation therapy for borderline resectable pancreatic cancer dependent on improved tumor-vessel relationships?. Journal of Clinical Oncology, 2013, 31, 4057-4057.	1.6	1
173	Clinicopathologic and Genetic Characterization of Traditional Serrated Adenomas of the Colon. American Journal of Clinical Pathology, 2012, 138, 356-366.	0.7	61
174	Keys to Personalized Care in Pancreatic Oncology. Journal of Clinical Oncology, 2012, 30, 4049-4950.	1.6	18
175	The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature, 2012, 486, 266-270.	27.8	297
176	CpG Island Methylator Phenotypeâ€“Positive Tumors in the Absence ofMLH1Methylation Constitute a Distinct Subset of Duodenal Adenocarcinomas and Are Associated with Poor Prognosis. Clinical Cancer Research, 2012, 18, 4743-4752.	7.0	45
177	Genetic Basis of Pancreas Cancer Development and Progression: Insights from Whole-Exome and Whole-Genome Sequencing. Clinical Cancer Research, 2012, 18, 4257-4265.	7.0	122
178	Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. Gut, 2012, 61, 1085-1094.	12.1	130
179	Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas are Genetically Similar and Distinct From Well-differentiated Pancreatic Neuroendocrine Tumors. American Journal of Surgical Pathology, 2012, 36, 173-184.	3.7	468
180	Clinical Significance of the Genetic Landscape of Pancreatic Cancer and Implications for Identification of Potential Long-term Survivors. Clinical Cancer Research, 2012, 18, 6339-6347.	7.0	220

#	Article	IF	Citations
181	Rapid Characterization of Candidate Biomarkers for Pancreatic Cancer Using Cell Microarrays (CMAs). Journal of Proteome Research, 2012, 11, 5556-5563.	3.7	14
182	A new branch on the tree: Next-generation sequencing in the study of cancer evolution. Seminars in Cell and Developmental Biology, 2012, 23, 237-242.	5.0	33
183	Computational Modeling of Pancreatic Cancer Reveals Kinetics of Metastasis Suggesting Optimum Treatment Strategies. Cell, 2012, 148, 362-375.	28.9	369
184	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 2012, 491, 399-405.	27.8	1,741
185	Sessile serrated adenomas: high-risk lesions?. Human Pathology, 2012, 43, 1808-1814.	2.0	25
186	Personalized Medicine in Pancreatic Cancer: Prognosis and Potential Implications for Therapy. Journal of Gastrointestinal Surgery, 2012, 16, 1651-1652.	1.7	3
187	HMGA1 Induces Intestinal Polyposis in Transgenic Mice and Drives Tumor Progression and Stem Cell Properties in Colon Cancer Cells. PLoS ONE, 2012, 7, e30034.	2.5	93
188	Origin of metastases: Subspecies of cancers generated by intrinsic karyotypic variations. Cell Cycle, 2012, 11, 1151-1166.	2.6	21
189	Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity. Clinical Cancer Research, 2012, 18, 6519-6530.	7.0	60
190	Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Human Mutation, 2012, 33, 100-103.	2.5	263
191	DNA methylation biomarker candidates for early detection of colon cancer. Tumor Biology, 2012, 33, 363-372.	1.8	57
192	Deep Clonal Profiling of Formalin Fixed Paraffin Embedded Clinical Samples. PLoS ONE, 2012, 7, e50586.	2.5	42
193	Abstract 3961: Computational modeling of pancreatic cancer reveals growth and dissemination kinetics and suggests optimum treatment strategies. , 2012, , .		1
194	Abstract 5318: DPC4 loss results in the activation of alternative oncogenic pathways in pancreatic cancer. , 2012, , .		0
195	Abstract SY30-01: Evolution and dynamics of pancreatic cancer progression. , 2012, , .		0
196	Abstract 1269: Activation of diverse signaling pathways in pancreatic cancer revealed by phosphoproteomics. , 2012, , .		0
197	Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature, 2011, 475, 106-109.	27.8	1,831
198	Prevalence of the Alternative Lengthening of Telomeres Telomere Maintenance Mechanism in Human Cancer Subtypes. American Journal of Pathology, 2011, 179, 1608-1615.	3.8	423

#	Article	IF	Citations
199	Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development. Cell, 2011, 144, 27-40.	28.9	2,020
200	AGR2 Is a Novel Surface Antigen That Promotes the Dissemination of Pancreatic Cancer Cells through Regulation of Cathepsins B and D. Cancer Research, 2011, 71, 7091-7102.	0.9	124
201	Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget, 2011, 2, 627-637.	1.8	383
202	Establishment and Characterization of a New Cell Line, A99, From a Primary Small Cell Carcinoma of the Pancreas. Pancreas, 2011, 40, 905-910.	1.1	21
203	Histologic Variations in Juvenile Polyp Phenotype Correlate With Genetic Defect Underlying Juvenile Polyposis. American Journal of Surgical Pathology, 2011, 35, 530-536.	3.7	34
204	Sessile serrated adenomas and classical adenomas: An epigenetic perspective on premalignant neoplastic lesions of the gastrointestinal tract. International Journal of Cancer, 2011, 129, 1889-1898.	5.1	49
205	Genomic and Epigenomic Integration Identifies a Prognostic Signature in Colon Cancer. Clinical Cancer Research, 2011, 17, 1535-1545.	7.0	136
206	Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. Modern Pathology, 2011, 24, 1237-1247.	5.5	90
207	GATA6 Activates Wnt Signaling in Pancreatic Cancer by Negatively Regulating the Wnt Antagonist Dickkopf-1. PLoS ONE, 2011, 6, e22129.	2.5	83
208	Disruption of p16 and Activation of Kras in Pancreas Increase Ductal Adenocarcinoma Formation and Metastasis in vivo. Oncotarget, 2011, 2, 862-873.	1.8	89
209	Abstract 2438: BAMBI Is overexpressed in metastatic pancreatic cancers with genetically Intact TGF-Î² pathways: A potential mechanism to escape TGF-Î² signaling during metastasis formation. Cancer Research, 2011, 71, 2438-2438.	0.9	1
210	Abstract 931: HMGA1 drives expansion of the intestinal stem cell compartment in transgenic mice and tumor progression in colon cancer cells. , 2011, , .		0
211	Abstract 4291: Functional p38 mitoge-activated protein kinase activity restrains pancreatic cancer growth in vitro and correlates with improved eurvival of pancreatic cancer patients. , 2011, , .		0
212	Histopathologic Basis for the Favorable Survival after Resection of Intraductal Papillary Mucinous Neoplasm-Associated Invasive Adenocarcinoma of the Pancreas. Annals of Surgery, 2010, 251, 470-476.	4.2	210
213	Reprimo-like is a P53 Responsive Gene Whose Promoter Methylation May Predict for Radiation Responsiveness in Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 78, S129.	0.8	0
214	Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. British Journal of Cancer, 2010, 103, 649-655.	6.4	65
215	Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. Nature, 2010, 464, 610-614.	27.8	470
216	The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature, 2010, 467, 1109-1113.	27.8	1,200

#	Article	IF	Citations
217	Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature, 2010, 467, 1114-1117.	27.8	2,184
218	Cross-platform Comparison of Two Pancreatic Cancer Phenotypes. Cancer Informatics, 2010, 9, CIN.S5755.	1.9	1
219	Prognostic Significance of Tumorigenic Cells With Mesenchymal Features in Pancreatic Adenocarcinoma. Journal of the National Cancer Institute, 2010, 102, 340-351.	6.3	392
220	A Six-Gene Signature Predicts Survival of Patients with Localized Pancreatic Ductal Adenocarcinoma. PLoS Medicine, 2010, 7, e1000307.	8.4	202
221	HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. Modern Pathology, 2010, 23, 98-104.	5.5	75
222	Phase I Trial of Oxaliplatin, Infusional 5-Fluorouracil, and Leucovorin (FOLFOX4) With Erlotinib and Bevacizumab in Colorectal Cancer. Clinical Colorectal Cancer, 2010, 9, 297-304.	2.3	18
223	The Pancreas. , 2010, , 891-904.		3
224	Cronkhite-Canada Syndrome: Gastric Involvement Diagnosed by MDCT. Case Reports in Medicine, 2009, 2009, 1-4.	0.7	9
225	Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer. Science, 2009, 324, 1457-1461.	12.6	2,730
226	DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer. Journal of Clinical Oncology, 2009, 27, 1806-1813.	1.6	976
227	Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene. Science, 2009, 324, 217-217.	12.6	713
228	Integrin Î±2 Mediates Selective Metastasis to the Liver. Cancer Research, 2009, 69, 7320-7328.	0.9	75
229	Genetic Mutations Associated with Cigarette Smoking in Pancreatic Cancer. Cancer Research, 2009, 69, 3681-3688.	0.9	126
230	SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer. Clinical Cancer Research, 2009, 15, 4674-4679.	7.0	335
231	Methylation ofTFPI2in Stool DNA: A Potential Novel Biomarker for the Detection of Colorectal Cancer. Cancer Research, 2009, 69, 4691-4699.	0.9	204
232	Downregulation of sodium transporters and NHERF proteins in IBD patients and mouse colitis models: Potential contributors to IBD-associated diarrhea. Inflammatory Bowel Diseases, 2009, 15, 261-274.	1.9	107
233	HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Modern Pathology, 2009, 22, 43-49.	5.5	96
234	Epigenetic Changes in Cancer. Annual Review of Pathology: Mechanisms of Disease, 2009, 4, 229-249.	22.4	149

#	Article	IF	Citations
235	Increased Cyclooxygenase-2 Expression in Juvenile Polyposis Syndrome. Clinical Gastroenterology and Hepatology, 2009, 7, 93-97.	4.4	14
236	Beta-catenin Nuclear Labeling is a Common Feature of Sessile Serrated Adenomas and Correlates With Early Neoplastic Progression After BRAF Activation. American Journal of Surgical Pathology, 2009, 33, 1823-1832.	3.7	97
237	Cancer Gene Profiling in Pancreatic Cancer. Methods in Molecular Biology, 2009, 576, 279-292.	0.9	5
238	The Pathology and Genetics of Metastatic Pancreatic Cancer. Archives of Pathology and Laboratory Medicine, 2009, 133, 413-422.	2.5	186
239	The developmental transcription factor Gata4 is overexpressed in pancreatic ductal adenocarcinoma. International Journal of Clinical and Experimental Pathology, 2009, 3, 47-55.	0.5	11
240	Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9. Breast Cancer Research, 2008, 10, R91.	5.0	26
241	Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses. Science, 2008, 321, 1801-1806.	12.6	3,755
242	Occurrence of Colorectal Adenomas in Younger Adults: An Epidemiologic Necropsy Study. Clinical Gastroenterology and Hepatology, 2008, 6, 1011-1015.	4.4	58
243	Coordinated Epidermal Growth Factor Receptor Pathway Gene Overexpression Predicts Epidermal Growth Factor Receptor Inhibitor Sensitivity in Pancreatic Cancer. Cancer Research, 2008, 68, 2841-2849.	0.9	89
244	Frequent genomic copy number gain and overexpression of GATA-6 in pancreatic carcinoma. Cancer Biology and Therapy, 2008, 7, 1593-1601.	3.4	65
245	Copy number alterations in pancreatic cancer identify recurrentPAK4amplification. Cancer Biology and Therapy, 2008, 7, 1793-1802.	3.4	120
246	Increased expression of cytoplasmic HuR in familial adenomatous polyposis. Cancer Biology and Therapy, 2008, 7, 424-427.	3.4	27
247	Frequent Î²-Catenin Nuclear Labeling in Sessile Serrated Polyps of the Colorectum With Neoplastic Potential. American Journal of Clinical Pathology, 2008, 129, 416-423.	0.7	45
248	Absence of E-Cadherin Expression Distinguishes Noncohesive from Cohesive Pancreatic Cancer. Clinical Cancer Research, 2008, 14, 412-418.	7.0	145
249	Patchy Distribution of Pathologic Abnormalities in Autoimmune Pancreatitis. American Journal of Surgical Pathology, 2008, 32, 1762-1769.	3.7	35
250	Gene expression profiles associated with advanced pancreatic cancer. International Journal of Clinical and Experimental Pathology, 2008, 1, 32-43.	0.5	17
251	Differential expression of multiple genes in association with MADH4/DPC4/SMAD4 inactivation in pancreatic cancer. International Journal of Clinical and Experimental Pathology, 2008, 1, 510-7.	0.5	12
252	Blockade of Hedgehog Signaling Inhibits Pancreatic Cancer Invasion and Metastases: A New Paradigm for Combination Therapy in Solid Cancers. Cancer Research, 2007, 67, 2187-2196.	0.9	647

#	Article	IF	Citations
253	High Cancer-Specific Expression of Mesothelin (MSLN) Is Attributable to an Upstream Enhancer Containing a Transcription Enhancer Factorâ€“Dependent MCAT Motif. Cancer Research, 2007, 67, 9055-9065.	0.9	55
254	Enhanced sensitivity to IGF-II signaling links loss of imprinting ofIGF2to increased cell proliferation and tumor risk. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20926-20931.	7.1	97
255	Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays. Molecular Cancer Therapeutics, 2007, 6, 515-523.	4.1	26
256	Risk of colorectal cancer in juvenile polyposis. Gut, 2007, 56, 965-967.	12.1	228
257	Evaluation of GATA-4 and GATA-5 methylation profiles in human pancreatic cancers indicate promoter methylation patterns distinct from other human tumor types. Cancer Biology and Therapy, 2007, 6, 1546-1552.	3.4	33
258	Peritumoral Fibroblast SPARC Expression and Patient Outcome With Resectable Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2007, 25, 319-325.	1.6	372
259	Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer. Molecular Cancer Therapeutics, 2007, 6, 1079-1088.	4.1	30
260	Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status. Clinical and Experimental Metastasis, 2007, 23, 357-365.	3.3	56
261	Aberrant methylation ofReprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma. Cancer, 2006, 107, 251-257.	4.1	43
262	An In vivo Platform for Translational Drug Development in Pancreatic Cancer. Clinical Cancer Research, 2006, 12, 4652-4661.	7.0	407
263	When should one subtract background fluorescence in 2-color microarrays?. Biostatistics, 2006, 8, 695-707.	1.5	23
264	Identifying Allelic Loss and Homozygous Deletions in Pancreatic Cancer without Matched Normals Using High-Density Single-Nucleotide Polymorphism Arrays. Cancer Research, 2006, 66, 7920-7928.	0.9	78
265	Immunohistochemical and Genetic Evaluation of Deoxycytidine Kinase in Pancreatic Cancer: Relationship to Molecular Mechanisms of Gemcitabine Resistance and Survival. Clinical Cancer Research, 2006, 12, 2492-2497.	7.0	141
266	Sessile Serrated Adenomas With Low- and High-Grade Dysplasia and Early Carcinomas. American Journal of Clinical Pathology, 2006, 126, 564-571.	0.7	158
267	Optimizing targeted agents development in pancreatic cancer: A fine-needle aspirate biopsy (FNAB) based ex vivo and in vivo assay. Journal of Clinical Oncology, 2006, 24, 3002-3002.	1.6	0
268	Immunohistochemistry and <I>In Situ </I> Hybridization in Pancreatic Neoplasia. , 2005, 103, 067-088.		1
269	Nuclear Î²-Catenin Expression Distinguishes Deep Fibromatosis From Other Benign and Malignant Fibroblastic and Myofibroblastic Lesions. American Journal of Surgical Pathology, 2005, 29, 653-659.	3.7	302
270	RPL38, FOSL1, and UPP1 Are Predominantly Expressed in the Pancreatic Ductal Epithelium. Pancreas, 2005, 30, 158-167.	1.1	29

#	Article	IF	Citations
271	Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene, 2005, 24, 850-858.	5.9	144
272	Increased Cyclooxygenase-2 Expression in Duodenal Compared with Colonic Tissues in Familial Adenomatous Polyposis and Relationship to the â^'765G â†' C COX-2 Polymorphism. Clinical Cancer Research, 2005, 11, 4090-4096.	7.0	58
273	Assessment of epidermal growth factor receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis. Cancer Biology and Therapy, 2005, 4, 1381-1386.	3.4	35
274	Immortalizing the complexity of cancer metastasis: Genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biology and Therapy, 2005, 4, 548-554.	3.4	132
275	Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: A potential new target for therapy. Cancer Biology and Therapy, 2005, 4, 90-93.	3.4	71
276	Stromal responses to carcinomas of the pancreas: Juxtatumoral gene expression conforms to the infiltrating pattern and not the biologic subtype. Cancer Biology and Therapy, 2005, 4, 302-307.	3.4	35
277	Loss of Imprinting of Igf2 Alters Intestinal Maturation and Tumorigenesis in Mice. Science, 2005, 307, 1976-1978.	12.6	312
278	Pancreaticobiliary Cancers With Deficient Methylenetetrahydrofolate Reductase Genotypes. Clinical Gastroenterology and Hepatology, 2005, 3, 752-760.	4.4	40
279	Claudin 4 Protein Expression in Primary and Metastatic Pancreatic Cancer. American Journal of Clinical Pathology, 2004, 121, 226-230.	0.7	149
280	Large-Scale Allelotype of Pancreaticobiliary Carcinoma Provides Quantitative Estimates of Genome-Wide Allelic Loss. Cancer Research, 2004, 64, 871-875.	0.9	68
281	Telomere Length Abnormalities Occur Early in the Initiation of Epithelial Carcinogenesis. Clinical Cancer Research, 2004, 10, 3317-3326.	7.0	292
282	Gene expression profiling identifies markers of ampullary adenocarcinoma. Cancer Biology and Therapy, 2004, 3, 651-656.	3.4	35
283	Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3089-3094.	7.1	175
284	MAP2K4/MKK4 Expression in Pancreatic Cancer. Clinical Cancer Research, 2004, 10, 8516-8520.	7.0	65
285	Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression. Cancer Biology and Therapy, 2004, 3, 1254-1261.	3.4	73
286	Gene Expression Profiling Identifies Genes Associated with Invasive Intraductal Papillary Mucinous Neoplasms of the Pancreas. American Journal of Pathology, 2004, 164, 903-914.	3.8	190
287	Missense Mutations of MADH4. Clinical Cancer Research, 2004, 10, 1597-1604.	7.0	89
288	Pathologically and Biologically Distinct Types of Epithelium in Intraductal Papillary Mucinous Neoplasms. American Journal of Surgical Pathology, 2004, 28, 839-848.	3.7	440

#	Article	IF	Citations
289	Claudin 4 Protein Expression in Primary and Metastatic Pancreatic Cancer Support for Use as a Therapeutic Target. American Journal of Clinical Pathology, 2004, 121, 226-230.	0.7	80
290	Cathepsin D protein levels in colorectal tumors: divergent expression patterns suggest complex regulation and function. International Journal of Oncology, 2004, 24, 473-85.	3.3	2
291	Notch mediates TGFÎ±-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell, 2003, 3, 565-576.	16.8	627
292	Multicomponent Analysis of the Pancreatic Adenocarcinoma Progression Model Using a Pancreatic Intraepithelial Neoplasia Tissue Microarray. Modern Pathology, 2003, 16, 902-912.	5.5	363
293	Exploration of Global Gene Expression Patterns in Pancreatic Adenocarcinoma Using cDNA Microarrays. American Journal of Pathology, 2003, 162, 1151-1162.	3.8	450
294	Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis, 2003, 24, 193-198.	2.8	146
295	Gene Expression in Neoplasms of the Pancreas: Applications to Diagnostic Pathology. Advances in Anatomic Pathology, 2003, 10, 125-134.	4.3	13
296	Results of Pancreaticoduodenectomy for Lymphoplasmacytic Sclerosing Pancreatitis. Annals of Surgery, 2003, 237, 853-859.	4.2	178
297	Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers. Cancer Research, 2003, 63, 994-9.	0.9	100
298	Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Research, 2003, 63, 4158-66.	0.9	238
299	Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Research, 2003, 63, 8614-22.	0.9	336
300	Immunohistochemical Validation of a Novel Epithelial and a Novel Stromal Marker of Pancreatic Ductal Adenocarcinoma Identified by Global Expression Microarrays. American Journal of Clinical Pathology, 2002, 118, 52-59.	0.7	124
301	Almost All Infiltrating Colloid Carcinomas of the Pancreas and Periampullary Region Arise From In Situ Papillary Neoplasms. American Journal of Surgical Pathology, 2002, 26, 56-63.	3.7	135
302	Discovery of Novel Tumor Markers of Pancreatic Cancer using Global Gene Expression Technology. American Journal of Pathology, 2002, 160, 1239-1249.	3.8	271
303	Exploring the Host Desmoplastic Response to Pancreatic Carcinoma. American Journal of Pathology, 2002, 160, 91-99.	3.8	182
304	Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology, 2002, 123, 365-372.	1.3	124
305	Reed-Sternberg-like cells in lymph node aspirates in the absence of Hodgkin's disease: Pathologic significance and differential diagnosis. Diagnostic Cytopathology, 2002, 27, 335-339.	1.0	26
306	Pancreatic cancer. Current Problems in Cancer, 2002, 26, 176-275.	2.0	268

#	Article	IF	Citations
307	Colloid Carcinomas of the Pancreas and Periampullary Region. American Journal of Surgical Pathology, 2002, 26, 952-953.	3.7	3
308	Colchicine Effect in a Colonic Hyperplastic Polyp. Archives of Pathology and Laboratory Medicine, 2002, 126, 615-617.	2.5	12
309	The desmoplastic response to infiltrating breast carcinoma: gene expression at the site of primary invasion and implications for comparisons between tumor types. Cancer Research, 2002, 62, 5351-7.	0.9	91
310	STK11/LKB1 Peutz-Jeghers Gene Inactivation in Intraductal Papillary-Mucinous Neoplasms of the Pancreas. American Journal of Pathology, 2001, 159, 2017-2022.	3.8	251
311	Colchicine Toxicity. American Journal of Surgical Pathology, 2001, 25, 1067-1073.	3.7	150
312	Intraductal Papillary Mucinous Neoplasms of the Pancreas: An Increasingly Recognized Clinicopathologic Entity. Annals of Surgery, 2001, 234, 313-322.	4.2	286
313	Molecular pathology of pancreatic cancer. Cancer Journal (Sudbury, Mass), 2001, 7, 251-8.	2.0	110
314	Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clinical Cancer Research, 2001, 7, 3862-8.	7.0	416
315	Dpc4 Protein in Mucinous Cystic Neoplasms of the Pancreas. American Journal of Surgical Pathology, 2000, 24, 1544-1548.	3.7	155
316	Dpc-4 Protein Is Expressed in Virtually All Human Intraductal Papillary Mucinous Neoplasms of the Pancreas. American Journal of Pathology, 2000, 157, 755-761.	3.8	245
317	Cathepsin B Activity and Protein Levels in Thyroid Carcinoma, Graves' Disease, and Multinodular Goiters. Thyroid, 1999, 9, 569-577.	4.5	25
318	Cytomegaloviral enterocolitis. Diseases of the Colon and Rectum, 1999, 42, 24-30.	1.3	102
319	Elevations in Cathepsin B Protein Content and Enzyme Activity Occur Independently of Glycosylation during Colorectal Tumor Progression. Journal of Biological Chemistry, 1997, 272, 29190-29199.	3.4	46